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Introduction
Streptococcus pneumoniae is an encapsulated, Gram-positive 
coccoid shaped, facultative anaerobic bacterium. In addition, 
S. pneumoniae is alpha-hemolytic under aerobic conditions 
and beta-hemolytic under anaerobic conditions. It can be 
distinguished from other Streptococcus species using optochin 
and bile susceptibility tests, although there are exceptions. The 
organism is somewhat fastidious, and thus only 20-30% of 
pneumococcal pneumonia cases are blood culture positive [1, 2]. 
Due to its fastidious nature and other factors, such as autolysin 
production in the stationary growth phase [3, 4], culture 
remains difficult. There are 90 serotypes of S. pneumoniae, but 
a much smaller subset of these cause significant human disease, 
making vaccine development a successful endeavor in reducing 
disease in at-risk populations [5, 6]. 
The CDC states that there are 400,000 hospitalizations per 
year in the US, and 36% of Community-acquired pneumonia 
is due to pneumococcus [7]. Of these cases, 25-30% become 
bacteremic, with an overall mortality rate of 5-7% [7]. Adults 
most commonly present with pneumonia after a brief one to 
three-day incubation period. After an abrupt onset of fever and 
chills, other symptoms such as chest pain, productive cough, 
shortness of breath, malaise and weakness may follow [7]. 
Complications of pneumococcal pneumonia include empyema, 
pericarditis and respiratory failure. According to the most recent 
2013 Active Bacterial Core Surveillance (ABCs) Report from the 
CDC’s Emerging Infections Program Network [8], 
S. pneumoniae was the cause of 69.1% of cases of pneumonia 
with bacteremia; 16.7% of cases of bacteremia (with no focus); 
and 6.4% of cases of meningitis based on a survey population 
of over 30 million people. In this population-based survey, 
invasive S. pneumoniae in children <4 years of age comprised 
6.42% of all cases and adults >65 years of age comprised 37.5% 
of all cases [8]. 
Since the year 2000, polyvalent vaccines that cover 7, 13 or 23 
different serotypes have been used to protect the most vulnerable 
populations. The pneumococcal conjugate vaccine (PCV13) is 
administered as a series for children under two years of age and 
adults 65 years and older [9]. The pneumococcal polysaccharide 
vaccine (PPSV23) is recommended for adults age 65 years and 
older, as well as anyone two years old and above at high risk of 
disease [9]. Persons who are immunocompromised, smoke or 
have asthma, are also candidates for these vaccines. While the 
introduction of vaccines that protect against multiple common 
S. pneumoniae serotypes has reduced pneumococcal disease 
significantly, cases still occur. Invasive pneumococcal disease is 
on the national notifiable diseases list, as well as the Kentucky 
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Abstract
Community-acquired pneumonia (CAP) due to Streptococcus pneumoniae still occurs in at risk 
populations, despite the availability of effective vaccines. Laboratory confirmation of S. pneumoniae 
remains challenging in cases of CAP despite advances in blood culture techniques and the 
availability of nucleic acid amplification tests such as PCR-based methods. Urine specimens are an 
attractive sample type because they are non-invasive compared to bronchial washes or whole blood 
specimens for patients with CAP. While urine specimens have been used successfully in antigen 
detection assays, they have not been extensively evaluated for PCR-based assays. In this preliminary 
study, we evaluated the potential for a real-time PCR assay targeting the S. pneumoniae autolysin 
gene (lytA) to detect in archived urine samples from patients with CAP. Results indicate that the real 
time lytA PCR assay on the Luminex ARIES® system shows promise as a screening tool for patients 
with CAP based on comparison to urine antigen detection assay results.
ORIGINAL RESEARCH
Reportable Diseases and Conditions list, and tracking drug 
resistance patterns remains important. As of 2013, the ABCs 
report indicated that among 2898 isolates of S. pneumoniae, 
2.2% were resistant to penicillin, 28.2% were resistant to 
erythromycin and 10.3% were resistant to tetracycline [8]. 
Laboratory diagnosis remains challenging for S. pneumoniae, 
however. Available diagnostic testing methods fall into three 
major categories at this time, including microscopy with 
microbiological culture, urine antigen detection assays and 
molecular testing such as PCR on cerebrospinal fluid (CSF), 
sputum or whole blood; however, no gold standard has been 
agreed upon. Molecular diagnostic testing is attractive, due to 
increased speed and sensitivity. One promising PCR target is 
the lytA gene of S. pneumoniae because the lytA gene is specific 
to S. pneumoniae [1]. This gene encodes a well-documented 
virulence factor and has little genetic variation within the 
species [10]. 
While lytA has been published as a promising PCR target for 
whole blood, sputum, serum samples, middle ear fluid and 
CSF specimen types [1, 2], it has not been tested extensively 
on urine samples. Our aim was to assess the feasibility of fully 
validating a rapid and sensitive PCR assay on the Luminex 
ARIES® platform using a non-invasive specimen type in order 
to detect S. pneumoniae from patients with a clinical diagnosis 
of pneumonia. The design of this study was to use archived urine 
samples from hospitalized patients with Community-acquired 
pneumonia (CAP) [11] for PCR analysis using the lytA gene 
target with Multicode® primers. Because previous laboratory 
results were available for these cases, the selected urine samples 
were either from patients with S. pneumoniae blood culture 
positive results or from patients, who by laboratory analysis, 
were negative for S. pneumoniae. In addition, urine samples 
from healthy volunteers were used as negative controls for 
this study. Preliminary results are promising for this assay and 
warrant further research and development.
Methods and Materials
Archived Urine Specimens: Sixty archived urine specimens 
were obtained from the University of Louisville Respiratory 
Biorepository in the Division of Infectious Diseases. Urine 
specimens selected for this study were collected between 2014-
2016 [11]. Briefly, the original urine samples from patients 
hospitalized with Community-acquired pneumonia (CAP) were 
held at 4°C, then processed within 28 hours of collection by 
adding 0.5 mL of 0.5M PIPES buffer (VWR, Radnor, PA, Part 
Number BB-121-250 mL) to 9.5 mL of urine. After mixing well, 
aliquots were frozen at -80°C in the Biorepository until thawed 
once for lytA PCR and BinaxNOW® S. pneumoniae antigen card 
testing. Aliquots of 200 μL of archived urine samples were used 
from 30 pneumococcus negative patients (having no laboratory 
evidence of Streptococcus pneumoniae infection) and 30 
patients having Streptococcus pneumoniae blood culture 
positive results. 
Fresh Urine Specimens (Negative Controls): An additional 30 
fresh urine samples were collected from healthy volunteers. 
These urine samples were collected and stored at 4°C less 
than 28 hours prior to processing by adding 0.5 mL of 0.5M 
PIPES buffer to 9.5 mL of urine. They were tested first after 
refrigerating, and again after freezing once at -20°C for 1-4 
weeks, with no change in lytA PCR or BinaxNOW® test results. 
ARIES® Instrument, ReadyMix®, Cassettes and PCR Analysis: 
The universal thermal profile settings on the ARIES® 
instrument were used for PCR. Cassettes (Part Number 50-
10026) and ReadyMix® (Part Number 3697) were purchased 
from Luminex (Austin, TX). The ARIES® software automatically 
generated the amplification and melt curves and assigned the 
corresponding cycle threshold (Ct) and melting temperature 
(Tm) values. Specimens were considered positive only if lytA 
and the specimen processing control Mouse Hepatitis Virus-2 
(MHV2) were detected in the Ct and Tm ranges established for 
this assay (see Table 1). A sample was called “Invalid” if the 
MHV2 amplification failed. 
Reagents: MultiCode® primer pairs for the Streptococcus 
pneumoniae lytA gene were obtained from Integrated DNA 
Technologies, Inc. (Coralville, IA). The MultiCode® primer 
sequence for lytA forward primer is /56-FAM//iMe-isodC/A 
CGC AAT CTA GCA GAT GAA GCA and the reverse primer is 
CTC CCT GTA TCA AGC GTT TTC GGC, based on a previous 
publication [1]. The MHV2 primer set (proprietary primer 
sequences, Luminex, Part Number 3803) was used as the sample 
processing control (SPC) in order to confirm that PCR inhibitors 
were not present. Furthermore, melt curve (Tm) data allows for 
calibration of detected melting temperatures for both lytA and 
MHV2 PCR amplifications. The lytA primer set was assigned 
to the FAM channel and MHV2 primer set was assigned to the 
AP525 channel. 
Primer Pool Preparation: 50 μL of 5 µM lytA forward primer, 
50 μL of 5 µM lytA reverse primer  and 100 μL of MHV2 primer 
set were mixed together. Frozen aliquots of the primer mix 
were stored at -20°C. From these aliquots, 4 μL of the primer 
pool (giving a final concentration of 200 nM) were used per 
ReadyMix® vial. 
Control Material: Titered Streptococcus pneumoniae 
(ZeptoMetrix, Buffalo, NY, Part Number 0801439) was 
purchased and used for accuracy and analytical sensitivity 
studies by diluting it in negative urine specimens at various 
concentrations. Urine samples were screened by the 
BinaxNOW® S. pneumoniae antigen card and lytA PCR assay 
prior to use to ensure specimens were negative by both methods. 
Analytical Sensitivity and Precision: For analytical sensitivity, 
the limit of detection (LOD) was determined for the lytA target 
using titered S. pneumoniae in negative urine (screened by 
BinaxNOW® S. pneumoniae antigen card and lytA PCR assay). 
S. pneumoniae was spiked into negative urine specimens using 
0.2 mL aliquots per cassette at 1 x 103 CFU/mL (200 CFU/
cassette), 1 x 102 CFU/mL (20 CFU cassette), 1 x 101 CFU/
mL (2 CFU/cassette), 1 x 100 CFU/mL (0.2 CFU/cassette), 1 
x  10-1 CFU/mL (0.02 CFU/cassette), 1 x 10-2 CFU/mL (0.002 
CFU/cassette) concentrations and tested. The LOD assay was 
repeated three times, independently, to demonstrate inter-assay 
precision as well as sensitivity. 
Accuracy: For the accuracy study, 11 known negative urine 
samples and 16 known positive samples, made up of various 
concentrations of Streptococcus pneumoniae that were spiked 
into negative urine (screened by BinaxNOW® S. pneumoniae 
antigen card and lytA PCR assay). Samples were blinded and 
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Clinical Criteria 
Invasive Pneumococcal (Streptococcus pneumoniae) Disease, or IPD, causes 
many clinical syndromes, depending on the site of infection (e.g., 
bacteremia, meningitis.) 
 
Laboratory Criteria for Diagnosis 
Supportive: Identification of S. pneumoniae from a normally sterile body site 
by a culture independent diagnostic test [CIDT] without isolation of the 
bacteria.  
Confirmatory: Isolation of S. pneumoniae from a normally sterile body site. 
 
Comments 
The use of CIDTs as stand-alone tests for the direct detection of S. 
pneumoniae from clinical specimens is increasing. Data regarding their 
performance indicate variability in the sensitivity, specificity, and positive 
predictive value of these assays depending on the manufacturer and 
validation methods used. It is therefore useful to collect information on the 
laboratory conducting the testing, and the type and manufacturer of the 
CIDT used to diagnose each IPD case. Culture confirmation of CIDT-
positive specimens is still the ideal method of confirming a case 
of IPD. 
	
tested by staff members that did not prepare the accuracy panel.
Box 1 Council of State and Territorial Epidemiologists 
(CSTE) Case Definition [12] 
Data Analysis: Mean and standard deviation were calculated 
using Microsoft Excel. The MEDCALC Diagnostic Test Evaluation 
tool was used to determine analytic sensitivity and
specificity [13]. Luminex SYNCT® software was used to analyze 
the PCR data. The highest Ct value for an lytA true positive was 
40.4, so the lytA target was set at 40.5 (Table 1). The mean of 
the Tm for an lytA true positive was 79.21°C, and was used as the 
melt curve window ± 2, and 20% of deepest Tm Δ RFU (change in 
relative fluorescence units) was set as Tm  peak threshold cutoff 
(Table 1). The SPC MHV2 cutoff was set the same way as the S. 
pneumoniae lytA. After completing PCR assay data analysis, cut 
off values were fixed on the SYNCT® software (Table 1) assay file 
and locked on the ARIES® instrument for subsequent specimen 
testing. 
Table 1 ARIES lytA PCR Assay Conditions
Alere BinaxNOW® S. pneumoniae Antigen Card: For this study,
90 urine specimens were tested by BinaxNOW®, 30 from each
group described in “Specimens” section. Urine samples were
screened following the manufacturer’s instructions [14]. Briefly,
the swab provided with the Alere kit was dipped into the
urine specimen to be tested, the swab was placed in the
BinaxNOW® device, and three drops of reagent were added to 
swab. Result was read at 15 minutes. Per the package insert (14), 
the limit of detection if 105 cells/mL or 1:250 dilution of a known 
positive patient urine.
Results
The analytical sensitivity for Streptococcus pneumoniae in urine 
with this PCR assay was 10 CFU/mL. Results are represented in 
Table 2 as mean ± standard deviation, calculated from three 
independent experiments. No mean and standard deviation 
were calculated for the 1 CFU/mL concentration, which was only 
positive in one out of three runs (33%). Inter-assay precision, as 
illustrated by the small standard deviations for Ct values and Tm 
values (Table 2), was excellent. There was little variation among 
three independent runs at the 1000 CFU/mL, 100 CFU/mL and 



























Table 2 Streptococcus pneumoniae PCR LOD
The accuracy of the assay was tested using a blinded panel 
of negative urine samples spiked with known quantities of S. 
pneumoniae. There were no false negative results, but one 
apparent “false” positive result. This was from a sample spiked 
with 1 CFU/mL, which is below the established LOD, but S. 
pneumoniae was present in sample. We found that this level 
could be detected 33% of the time (Table 2). Based on results 
shown in Table 3, the sensitivity was 100% [95% Confidence 
Interval (CI) 79.41% to 100%] and the specificity was 90.91% 
(95% CI 58.71% to 99.77%). 
Table 3 Accuracy of lytA PCR Assay in Urine Spiked with S. pneumoniae
The performance of the lytA PCR assay was compared to the 
BinaxNOW® S. pneumoniae urine antigen test using clinical 
samples (Table 4). These 90 clinical samples consisted of 
three different groups as indicated in Table 4. Archived urine 
samples from patients with CAP, but no laboratory evidence of S. 
pneumoniae infection, were tested with the lytA PCR assay and 
the BinaxNOW® S. pneumoniae assay. This group was comprised 
of 16 females (53.3%) and 14 males (46.7%) with an average age 
of 60.7 years (range 31-81 years old). Three (3) samples were lytA 
PCR positive out of 30 negative urine sample tests, giving a 10% 
PCR positivity rate for S. pneumoniae on this sample set (Table 
4). No inhibition was observed based on MHV2 Ct values and Tm 
data. BinaxNOW® S. pneumoniae antigen results for this clinical 
sample was 100% negative (30/30) (Table 4), which gave the 
lytA PCR assay a 90% specificity (95% CI 73.47% to 97.8%). A 
second set of archived urine samples from patients with CAP who 
were blood culture positive for S. pneumoniae were also tested 
by lytA PCR and BinaxNOW®. This group was comprised of 15 
females (50%) and 15 males (50%), with an age range of 20 to 100 
years old (average 63.5 years). Of this group, 13 out of 30 urine 
samples were lytA positive by PCR, giving a 43.3% positivity 
rate for this sample set (Table 4). No inhibition was observed 
bazsed on MHV2 Ct and Tm data. BinaxNOW® S. pneumoniae 
urine antigen results for this sample set was 83.3% in agreement 
(25/30 total results) with ] the lytA PCR assay (Table 4). It is 
interesting to note that there were five (16.7%) discrepant results 
(3 lytA PCR positive, but BINAX NOW negative; 2 lytA PCR 
negative, but BINAX NOW positive). Comparing performance 
of the lytA PCR assay to BinaxNOW® S. pneumoniae urine 
antigen results for the blood culture positive group as the “gold 
standard,” the sensitivity of the PCR assay was 85.71% (95% 
CI 57.91% to 98.22%) while the specificity was 85.71% (95% CI 
63.66% to 96.95%).
	
Sample	ID	 lytA	Ct	±SD	 lytA	Tm	±SD	 MHV2	Ct	±SD	 MHV2	Tm	±SD	
S.	pneumoniae	1000	CFU/mL	 30.4	±0.44	 79.25±0.1	 24±0.46	 77.56±0.32	
S.	pneumoniae	100	CFU/mL	 34.23±1.1	 79.12±0.06	 24.6±1.47	 77.4+0.46	
S.	pneumoniae	10	CFU/mL	 37.13±1.63	 79.22±0.12	 23.97±0.5	 77.53±0.21	
S.	pneumoniae	1	CFU/mL	 	38.2	 	79.5	 24.2±0.56	 77.47±0.32	
S.	pneumoniae	0.1	CFU/mL	 		 		 24.73±0.38	 77.47±0.35	






Table 4 Clinical Urine Sample Summary Results
The final group of 30 urines tested by lytA PCR and BinaxNOW® 
was from healthy volunteers consisting of 17 males (56.7%) 
and 13 females (43.3%), with an age range of 23 to 65 years 
old (average 34.6 years). None of these urine samples was lytA 
positive or BinaxNOW® antigen positive (Table 4), which 
gave the lytA PCR assay a 100% specificity. No inhibition was 
observed based on MHV2 Ct values and Tm data.
Specificity studies were not done in this preliminary study due to 
lytA PCR specificity data being available from three previously 
published studies also using the lytA target used in this report. 
Carvalho et al. [1] used an extensive strain collection from the 
CDC Streptococcus Laboratory to assess specificity of the lytA 
primer set. Carvalho demonstrated that using 5 ng/µL DNA 
extracted from 67 strains, representing 44 different serotypes 
of S. pneumoniae isolates, and 104 non pneumococcal isolates, 
there was 100% specificity for S. pneumoniae. In another study 
demonstrating specificity, Sheppard et al. [2] used a panel of 
59 isolates including 18 species of streptococci and 21 other 
closely related species or common pathogens and found no 
crossreactivity with an lytA primer set. Finally, McAvin et al. 
used 44 organisms from diverse genera and 26 negative control 
organisms, including 7 Streptococcus species, and also observed 
100% specificity with no cross-reactivity with an lytA PCR assay 
[10].
Discussion
The goal of this preliminary study was to assess the feasibility of 
fully validating the performance of an lytA PCR assay in urine 
specimens from patients diagnosed with CAP [11] for use in a 
future, prospective study. The lytA target was chosen due to 
several publications indicating high specificity of the autolysin 
gene for S. pneumoniae [1]. Using the Luminex ARIES® 
platform that automates DNA extraction, PCR amplification and 
real-time detection, we found that the MultiCode® lytA assay 
could reliably detect 10 CFU/mL in urine. Accuracy studies 
using negative urine samples spiked with known quantities of 
S. pneumoniae demonstrated 16/16 (100%) lytA positive for 
known positive samples and 10/11 (90.9%) lytA negative for 
known negative samples. With archived clinical samples, we 
observed 43.3% lytA positive urine samples from S. pneumoniae 
blood culture positive CAP patients and 10% lytA positive urine 
samples from CAP patients with no laboratory evidence of S. 
pneumoniae infection. None of the urine samples from 30 
healthy volunteers were positive for lytA. All 90 urine specimens 
were tested by the BinaxNOW® S. pneumoniae antigen card test 
as well as by PCR after one freeze-thaw cycle. The only group 
with any positive BinaxNOW® S. pneumoniae antigen results 
was the blood culture positive patients. The BinaxNOW® S. 
pneumoniae antigen card did not perform as well as stated in 
the package insert [14] in our study, however. The urine antigen 
detection assay BinaxNOW® for S. pneumoniae has a stated 
sensitivity of 86% and specificity of 94% [14] in adults, based 
on a retrospective study of urine specimens from blood culture 
positive patients. The package insert does not specify either the 
length of time or freezer temperature storage conditions that 
ensure the test results are valid for urine, thus it is possible that 
long-term storage at -80°C affected assay performance. As noted 
in our results, there were five discrepant results out of 30 CAP 
patients with S. pneumoniae positive blood cultures, but overall 
the two assays detected similar numbers of positive results in this 
group (Table 4). Three of these were lytA positive with the lytA 
PCR assay, but BinaxNOW® negative, while two patients were 
lytA negative but BinaxNOW® positive. Another explanation 
for the discrepant results (besides long-term storage at -80°C) 
is that the targets of each assay are different (DNA versus 
antigens). Further study of these patient specimens would be 
required to truly understand these interesting differences, 
as well as completing a prospective study with similar groups 
using fresh urine specimens rather than long-term frozen urine 
specimens. 
To place these results in context of other standard laboratory 
diagnostic tests, only 15-30% of patients with CAP due to S. 
pneumoniae have positive blood cultures [1, 2]. While numerous 
lytA PCR assays have been reported for use with multiple 
specimen types, urine has not been evaluated extensively. 
Whole blood was evaluated in one study for patients with either 
pneumococcal septicemia or with pneumococcal pneumonia 
with positive blood cultures [2]. For the septicemic patient 
group, 51.7% of the whole blood specimens were lytA positive, 
while for the pneumonia patient group, 39.5% were positive 
[2]. Additional testing by this group found that for 105 blood 
culture positive samples, 42.9% were positive for lytA [2]. This 
is in contrast to 100% of CSF specimens, sputum specimens and 
lung biopsy tissue giving positive results with the lytA PCR assay 
[2]. In a study by Murdoch et al. [15], using the pseudolysin 
(ply) gene instead of lytA, throat swabs and sputum specimens 
demonstrated 55% and 81% PCR positivity, respectively. Results 
for plasma, buffy coat and urine were 2% using the same ply 
PCR assay [13]. 
Despite the findings of these previous studies, urine remains 
an attractive specimen type due to its non-invasive collection 
method for patients with CAP. Urine antigen assays are widely 
used because they are rapid and perform well on adults [2] 
despite the highly variable carriage rate in healthy adults 
[5]. The BinaxNOW® S. pneumoniae urine antigen assay is 
not recommended pediatric patients, however, due to well- 
documented issues with S. pneumoniae nasopharyngeal 
carriage in children [16]. The potential benefit of PCR assays 
is the ability to quantify the amount of DNA present and to set 
thresholds for carriage versus infection rates. Future studies 
could address the utility of a quantitative PCR assay with urine 
from children suspected of having streptococcal infections. 
This preliminary study has some limitations. The first is that 
only the lytA autolysin gene target was used for PCR analysis 
in urine. Future studies may involve S. pneumoniae psaA 
MultiCode primer sets, or other published gene targets specific 
to S. pneumoniae, to serve as a confirmatory test after screening 
positive with the lytA PCR assay. A second limitation is that 
the urine samples were archived from patients hospitalized 
with CAP, stored at -80°C since January 2014. Repeated freeze 
thawing of certain sample types is known to reduce sensitivity of 



















13	(43.3)	 12	(40)	 17	(56.7)	 18	(60)	
Healthy	volunteers	 0	(0)	 0	(0)	 30	(100)	 30	(100)	
PCR assays and the effect of long term storage at -80°C on the 
BinaxNOW® antigen test remains unclear. Specimen stability 
experiments will need to be performed in a prospective study 
to  address these variables. Finally, the urine sample sizes are 
small due to the availability of archived urine samples that 
met the criteria established for this study (i.e. urine had to be 
from patients with CAP having a positive blood culture versus 
those patients having all negative laboratory results for S. 
pneumoniae). If the preliminary data hold true when testing 
additional urine from patients with CAP, then future studies 
could be performed to validate other MultiCode® primers on the 
ARIES® platform. Upon completion of the full validation study, 
a cost comparison of the lytA PCR assay and the urinary antigen 
test would be useful information. The potential to develop 
MultiCode® primer sets to detect key antibiotic resistance 
markers in addition to identifying Streptococcus pneumoniae 
would be an advance in laboratory diagnostics for patients with 
CAP. 
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